Gene · 2548
Papers2,709
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
381 to 400 of 2,709
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Proteomic Analysis of Ferrochelatase Interactome in Erythroid and Non-Erythroid Cells. | Life (Basel) | 2023 | 36836934 | PubTator, text mining | PubMed |
| Autophagy and the Insulin-like Growth Factor (IGF) System in Colonic Cells: Implications for Colorectal Neoplasia. | Int J Mol Sci | 2023 | 36835075 | PubTator, text mining | PubMed |
| Treatment Dilemma in Children with Late-Onset Pompe Disease. | Genes (Basel) | 2023 | 36833288 | PubTator, text mining | PubMed |
| Cardiovascular Disease as a Consequence or a Cause of Cancer: Potential Role of Extracellular Vesicles. | Biomolecules | 2023 | 36830690 | PubTator, text mining | PubMed |
| A Network Pharmacology Method Combined with Molecular Docking Verification to Explore the Therapeutic Mechanisms Underlying Simiao Pill Herbal Medicine against Hyperuricemia. | Biomed Res Int | 2023 | 36817858 | PubTator, text mining | PubMed |
| Phase I study of liver depot gene therapy in late-onset Pompe disease. | Mol Ther | 2023 | 36805083 | PubTator, text mining | PubMed |
| Expert-opinion-based guidance for the care of children with lysosomal storage diseases during the COVID-19 pandemic: An experience-based Turkey perspective. | Front Public Health | 2023 | 36794069 | PubTator, text mining | PubMed |
| Copy number variants from 4800 exomes contribute to ~7% of genetic diagnoses in movement disorders, muscle disorders and neuropathies. | Eur J Hum Genet | 2023 | 36781956 | PubTator, text mining | PubMed |
| 4-Methylumbelliferone Targets Revealed by Public Data Analysis and Liver Transcriptome Sequencing. | Int J Mol Sci | 2023 | 36768453 | PubTator, text mining | PubMed |
| Establishment and characterization of canine mammary tumoroids for translational research. | BMC Biol | 2023 | 36737789 | PubTator, text mining | PubMed |
| Gene therapy for lysosomal storage diseases: Current clinical trial prospects. | Front Genet | 2023 | 36713078 | PubTator, text mining | PubMed |
| Hydroxylated polycyclic aromatic hydrocarbons possess inhibitory activity against alpha-glucosidase: An in vitro study using multispectroscopic techniques and molecular docking. | Spectrochim Acta A Mol Biomol Spectrosc | 2023 | 36689906 | PubTator, text mining | PubMed |
| Bioactive and Sensory Di- and Tripeptides Generated during Dry-Curing of Pork Meat. | Int J Mol Sci | 2023 | 36675084 | PubTator, text mining | PubMed |
| Curcumin Has Beneficial Effects on Lysosomal Alpha-Galactosidase: Potential Implications for the Cure of Fabry Disease. | Int J Mol Sci | 2023 | 36674610 | PubTator, text mining | PubMed |
| Polymer-based drug delivery systems under investigation for enzyme replacement and other therapies of lysosomal storage disorders. | Adv Drug Deliv Rev | 2023 | 36657645 | PubTator, text mining | PubMed |
| Model-Informed Approach Supporting Approval of Nexviazyme (Avalglucosidase Alfa-ngpt) in Pediatric Patients with Late-Onset Pompe Disease. | AAPS J | 2023 | 36653728 | PubTator, text mining | PubMed |
| Comparative site-specific N-glycoproteome analysis reveals aberrant N-glycosylation and gives insights into mannose-6-phosphate pathway in cancer. | Commun Biol | 2023 | 36639722 | PubTator, text mining | PubMed |
| Neurobehavioral deficits of mice expressing a low level of G127V mutant frataxin. | Neurobiol Dis | 2023 | 36638893 | PubTator, text mining | PubMed |
| Infantile-onset Pompe disease with neutropenia: Treatment decisions in the face of a unique phenotype. | JIMD Rep | 2023 | 36636589 | PubTator, text mining | PubMed |
| FXN gene methylation determines carrier status in Friedreich ataxia. | J Med Genet | 2023 | 36635061 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2548/papers?page=20